Bank of New York Mellon Corp Acquires 152,619 Shares of Thermo Fisher Scientific Inc. $TMO

Bank of New York Mellon Corp grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,724,476 shares of the medical research company’s stock after purchasing an additional 152,619 shares during the quarter. Bank of New York Mellon Corp’s holdings in Thermo Fisher Scientific were worth $2,158,148,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of TMO. Palatine Hill Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $256,000. Westpac Banking Corp raised its holdings in Thermo Fisher Scientific by 45.2% in the 4th quarter. Westpac Banking Corp now owns 12,617 shares of the medical research company’s stock worth $7,311,000 after acquiring an additional 3,930 shares during the period. Greenwich Wealth Management LLC lifted its position in Thermo Fisher Scientific by 47.0% during the 4th quarter. Greenwich Wealth Management LLC now owns 816 shares of the medical research company’s stock worth $473,000 after acquiring an additional 261 shares during the last quarter. Meridian Management Co. grew its position in shares of Thermo Fisher Scientific by 3.9% in the fourth quarter. Meridian Management Co. now owns 10,782 shares of the medical research company’s stock valued at $6,248,000 after purchasing an additional 409 shares during the last quarter. Finally, Natixis Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 22.0% in the fourth quarter. Natixis Advisors LLC now owns 588,805 shares of the medical research company’s stock worth $341,183,000 after purchasing an additional 106,375 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Barclays cut their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. DZ Bank began coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price target for the company. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Finally, Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $612.24.

Thermo Fisher Scientific Stock Down 2.7%

Shares of TMO opened at $480.62 on Wednesday. The business’s 50 day simple moving average is $480.40 and its 200-day simple moving average is $533.68. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a market capitalization of $178.61 billion, a P/E ratio of 26.42, a PEG ratio of 2.19 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same quarter in the previous year, the firm earned $5.15 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.